• IA Announce the Acceptance of 2 Abstracts from Clinical Studies in Rheumatoid and Juvenile Rheumatoid Arthritis at EULAR 2017 Image Analysis Group (IA-Group) announces the acceptance of two abstracts from clinical  studies in Rheumatoid and Juvenile Rheumatoid Arthritis by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June. To schedule a meeting with the team please email to:  Following is a list of accepted abstracts: “Quantification ...
  • Importance of Advanced Imaging in Brain Cancer Therapy R&D Glioblastoma (GBM) is the aggressive and most common form of brain cancer. The efficient treatment of GBM is still an unmet clinical need. The complex nature of the tumour itself requires not only more advanced therapies but also more advanced insights and methods to proof therapy efficacy. Why is GBM therapy so difficult? Many GBM treatment attempts have ...
  • IA Announce FDA 510(k) Clearance for Dynamika Platform and a New Release with Advanced Imaging and RECIST Scoring Image Analysis Group (IA-Group), expert imaging clinical research organization are pleased to announce FDA (U.S. Food and Drug Administration) 510(k) clearance of their proprietary cloud-based software platform DYNAMIKA. DYNAMIKA is a powerful cloud platform for management, review and automated scoring of imaging data in clinical trials. It has been cleared by the FDA for the display, analysis and ...
  • IA’s team at ASCO annual meeting on June 2–6, 2017, at McCormick Place, Chicago Meet IA’s team at the American Society of Clinical Oncology (ASCO) annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The group’s CEO, Dr. Olga Kubassova and Head of R&D, Dr. Diana Roettger will be attending the meeting to present and discuss the Company’s work in oncology and immuno-oncology. In particular, the use of advanced ...
  • Drug Development in Osteoarthritis Despite millions of sufferers around the world and the market valued at over $3.5 billion a year, osteoarthritis treatment still largely relies on cheap generic drugs. Only a few companies have disease-modifying biologic drugs at the late stage of development. Among them: Tissuegene, Nordic Biosciences / Merck and Seikagaku. Several others are developing drugs for ...

What Our Clients Say

  • Dynamika is really fantastic! Salvatore Costantino, Post Doctoral Researcher, University of Sassari, Italy
  • I feel strongly that by making Dynamika available, student researchers could come up with very interesting and meaningful quantitative projects. Laura, Radiographer
  • Dynamika is key to precise and accurate early diagnostics and a powerful tool for follow-up of post-op and post chemo and/or radio treatment patients. Roman Marin, Head of CT and MRI Department
  • I am a clinical-research fellow with high experience in prostate MRI analysis and reporting. I have been using Dynamika mostly to help the analysis support team to develop a PI-RADS structured reporting user interface.
    The software is extremely useful and has the potential to be used in daily clinical practice. One of the most important skills of Dynamika is the capability of providing high quality tools to report prostate mpMRIs together with the possibility of assessing quantitative analysis at the same time.
    Therefore, Dynamika opens a new window in the use of automated and semi-automated algorithms both for clinical and research purposes.
    The integration of these two aspects is further strengthened by the remarkable competence of the support team that is constantly willing to help me when necessary.
    I hope to keep on working with Dynamika and taking advantage of all its valuable tools during my clinical-research practice.
    Francesco Giganti- Clinical Research Fellow, University College Hospital, London, UK
  • We have been using Dynamika software to analyse DCE data as part of a research project using multiparametric MRI for targeted radiotherapy treatment planning. We have found the software extremely useful compared with software delivered with our MRI scanner for a number of reasons, in particular: the ability to control each stage of the data processing, the ability to assess image quality and examine the parametric and pharmacokinetic maps in detail. Our project requires a quantitative (rather than qualitative) analysis of the DCE data and we have been very impressed with the collaborative approach of the Image Analysis support team in helping us achieve our goals. In addition, we commend the support team in providing informative and responsive training sessions and willingness to develop the software to meet the needs of our research project. Hayley Reynolds, Research Fellow, The Peter MacCullum Cancer Centre, Melbourne, Australia